7157-15-5

Usage

Uses

Used in Scientific Research:
2-Bromomandelic Acid is used as a chemical compound in scientific research, particularly in synthetic chemistry, for its potential reactivity and aromatic properties. It serves as a precursor or intermediary to other compounds, making it valuable in the development of new substances and materials.
Used in Synthetic Chemistry:
2-Bromomandelic Acid is used as a precursor in synthetic chemistry for the synthesis of various organic compounds. Its unique structure, which includes a phenolic ring and a carboxylic acid group, allows it to participate in a range of chemical reactions, contributing to the creation of new molecules with potential applications in various fields.
Used in Pharmaceutical Industry:
2-Bromomandelic Acid is used as a chemical intermediate in the pharmaceutical industry for the synthesis of drugs and drug candidates. Its reactivity and structural features make it a useful building block in the development of new medications, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Production:
2-Bromomandelic Acid is used as a chemical intermediate in the production of various industrial chemicals. Its versatility in chemical reactions allows it to be incorporated into the synthesis of a wide range of products, from specialty chemicals to consumer goods.

InChI:InChI=1/C8H7BrO3/c9-6-4-2-1-3-5(6)7(10)8(11)12/h1-4,7,10H,(H,11,12)

Upstream product

• 70-11-1 α-bromoacetophenone 
• 6630-33-7 ortho-bromobenzaldehyde 
• 18698-97-0 ortho-bromophenylacetic acid 
• 52923-21-4 2-(2-bromophenyl)-2-hydroxyacetonitrile 
• 2142-69-0 2-bromophenyl methyl ketone 
• 75-25-2 Bromoform 

Downstream Products

• 32345-77-0 (R)-(-)-2-bromo-mandelic acid 
• 1236046-50-6 (2-bromophenyl)(2-(pyridin-2-yl)phenyl)methanone 
• 6630-33-7 ortho-bromobenzaldehyde 
• 21165-13-9 methyl 2-(2-bromophenyl)-2-hydroxyacetate 
• 181040-14-2 methyl (RS)-(2-bromophenyl)-[2-cyano-5-(thien-3-ylmethoxy)phenoxy]acetate 
• 43063-97-4 methyl 2-bromo-2-(2-bromophenyl) acetate 
• 30297-34-8 5-(2-bromo-phenyl)-2-dimethylamino-oxazol-4-one 
• 1402890-79-2 methyl 2-(tert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)phenyl]acetate 
• 1402890-78-1 methyl 2-(2-bromophenyl)-2-(tert-butoxy)acetate 
• 1402890-71-4 2-(tert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)phenyl]acetic acid 

Relevant academic research and scientific papers

Nitrilases, nucleic acids encoding them and methods for making and using them

The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.

Solid phase behavior in the chiral systems of various 2-hydroxy-2-phenylacetic acid (mandelic acid) derivatives

The solid phase behavior of a series of monosubstituted F-, Cl-, Br-, I-, and CH3- and two 2,4-halogen-disubstituted 2-hydroxy-2-phenylacetic acid (mandelic acid) derivatives was investigated. The study includes detailed information about melting temperature, melting enthalpy, X-ray diffraction data, as well as selected binary phase diagrams of the respective chiral systems. Aside from the known metastable conglomerate 2-chloromandelic acid, evidence for two more metastable conglomerates was found.

Relationships between the racemic structures of substituted mandelic acids containing 8- and 10-membered hydrogen bonded dimer rings

The structures of 27 monosubstituted mandelic acids, including several of their polymorphs, plus unsubstituted mandelic acid itself (two polymorphs) are investigated for structural similarity. The results, presented pictorially as a structural relationship plot, show that rather more structures are built up from the carboxyl-chain hydroxyl hydrogen bonded dimer than from the conventional carboxylic acid dimer. The results show how all the structures are related and, based on the two types of dimer, the degree of similarity that they possess. Some structures with Z′ > 1 contain both sorts of dimers and there are many examples of isostructural sets within the structures so far determined. We also present an example where analysing similarity in related families of structures highlights a structure that should be present and which has indeed then proceeded to be synthesised and determined.

Amberlyst A-26: An efficient and reusable heterogeneous catalyst for a one-pot oxidation-Cannizarro reaction

Amberlyst A-26 catalyses the efficient synthesis of α-hydroxy- arylacetic acids from aryl methyl ketones in the presence of SeO2. After simple separation, the catalyst does not lose its activity and can be reused without significant loss in activity for at least four cycles.

Inhibitors of viral replication, their process of preparation and their therapeutical uses

The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES

The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

Ytterbium triflate-promoted tandem one-pot oxidation-cannizzaro reaction of aryl methyl ketones

(Chemical Equation Presented) Ytterbium triflate was shown to be an effective catalyst in promoting the synthesis of either isopropyl esters or free α-hydroxy-arylacetic acids from substituted aromatic glyoxals and aryl methyl ketones, respectively. The reaction to provide acids starting from differently substituted ketones was carried out by an environmentally friendly method using an aqueous medium as a solvent and giving the adducts in 78-99% yield without any further purification after the usual workup.

Dipeptide inhibitors of β-secretase

Dipeptide derived inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and in pharmaceutical compositions.